A study To assess the incidence of arrhythmia and/or cardiac conduction disorder during the first twelve months of dulaglutide treatment among patients with Type- 2 Diabetes Mellitus: post authorization safety study (PASS)
Latest Information Update: 10 Dec 2020
At a glance
- Drugs Dulaglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Acronyms PASS
Most Recent Events
- 10 Dec 2020 New trial record